What is the story about?
What's Happening?
Accord BioPharma, a division of Intas Pharmaceuticals, has announced the commercial launch of IMULDOSA, a biosimilar to STELARA, priced at the lowest wholesaler acquisition cost among branded ustekinumab biosimilars. This launch aims to expand patient access to biologic therapies for conditions such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The company is committed to reducing costs and providing comprehensive patient support services. IMULDOSA is FDA-approved for the same indications as STELARA, and Accord BioPharma is offering a $0 co-pay program for eligible patients.
Why It's Important?
The launch of IMULDOSA is significant as it addresses the high cost barrier associated with biologic therapies, potentially increasing access for millions of Americans suffering from chronic immune-mediated inflammatory conditions. By offering a biosimilar at a 92% discount from STELARA, Accord BioPharma is making strides in transforming the treatment landscape and providing more affordable healthcare options. This move could lead to broader adoption of biosimilars, driving down healthcare costs and improving patient outcomes.
What's Next?
Accord BioPharma plans to continue expanding its portfolio and pipeline, including the introduction of additional biosimilars to the U.S. market. The company is also focused on enhancing patient support services and resources to ensure comprehensive care. As the biosimilar market grows, stakeholders such as healthcare providers and insurers may need to adapt to the increased availability and affordability of these therapies.
AI Generated Content
Do you find this article useful?
